1. Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT
- Author
-
Hiroyasu Ogawa, Yoshiko Atsuta, Ritsuro Suzuki, T Fukuda, Tokiko Nagamura-Inoue, Chiaki Nakaseko, N Yamagata, S Taniguchi, Tomoki Naoe, Tetsuya Nishida, Makoto Murata, Hisashi Sakamaki, Hikaru Kobayashi, Yasuo Morishima, Kazuteru Ohashi, and Takehiko Mori
- Subjects
Male ,Transplantation Conditioning ,Blood transfusion ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,Gastroenterology ,Umbilical cord ,Japan ,Recurrence ,Cause of Death ,Registries ,Societies, Medical ,Bone Marrow Transplantation ,Hematopoietic Stem Cell Transplantation ,donor source ,hematopoietic SCT ,Hematology ,Middle Aged ,Fetal Blood ,Treatment Outcome ,medicine.anatomical_structure ,Female ,Original Article ,Cord Blood Stem Cell Transplantation ,engraftment ,Adult ,medicine.medical_specialty ,Allogeneic transplantation ,survival ,Young Adult ,idiopathic myelofibrosis ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Blood Transfusion ,Myelofibrosis ,Aged ,Proportional Hazards Models ,Retrospective Studies ,Transplantation ,business.industry ,Hematopoietic Stem Cells ,medicine.disease ,Surgery ,Primary Myelofibrosis ,Multivariate Analysis ,Mutation ,business - Abstract
To determine whether a difference in donor source affects the outcome of transplantation for patients with primary myelofibrosis (PMF), a retrospective study was conducted using the national registry data on patients who received first allogeneic hematopoietic cell transplantation (HCT) with related BM (n=19), related PBSCs (n=25), unrelated BM (n=28) or unrelated umbilical cord blood (UCB; n=11). The 5-year OS rates after related BM, related PBSC and unrelated BM transplantation were 63%, 43% and 41%, respectively, and the 2-year OS rate after UCB transplantation was 36%. On multivariate analysis, the donor source was not a significant factor for predicting the OS rate. Instead, performance status (PS) ⩾2 (vs PS 0–1) predicted a lower OS (P=0.044), and RBC transfusion ⩾20 times before transplantation (vs transfusion ⩽9 times) showed a trend toward a lower OS (P=0.053). No advantage of nonmyeloablative preconditioning regimens in terms of decreasing nonrelapse mortality or increasing OS was found. Allogeneic HCT, and even unrelated BM and UCB transplantation, provides a curative treatment for PMF patients.
- Published
- 2013
- Full Text
- View/download PDF